Array BioPharma

Array BioPharma
Company typeSubsidiary
Nasdaq: ARRY
IndustryOncology
Medication
Founded1998; 26 years ago (1998)
Founder
  • Drs. Tony Piscopio
  • Kevin Koch
  • David Snitman
  • K.C. Nicolaou
Headquarters,
United States
Revenue$173.8 million (2018)
ParentPfizer
Websitewww.arraybiopharma.com

Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.

History

[edit]

In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.[1]

In November 2000, the company became a public company via an initial public offering.[2]

In June 2019, Pfizer acquired the company for approximately $11 billion.[3]

Discovery of FDA Approved Small Molecules

[edit]

References

[edit]
  1. ^ "Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company". BioSpace. Retrieved 2020-07-28.
  2. ^ "Array IPO up 17%". CNN. November 17, 2000.
  3. ^ "Pfizer acquires Array BioPharma, valued at $11.4 billion". Rappler. 18 June 2019. Retrieved 2020-07-29.